This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ALLEN, J. K. Articles by FRASER, I. S. Search for Related Content PubMed PubMed Citation Articles by ALLEN, J. K. Articles by FRASER, I. S.

Cholesterol, High Density Lipoprotein and Danazol

Department of Biochemistry, Royal Prince Alfred Hospital Camperdown, New South Wales 2050
The Department of Obstetrics and Gynaecology, University of Sydney Sydney, New South Wales 2006, Australia

Address all correspondence and requests for reprints to: Prof. I. S. Fraser, Department of Obstetrics and Gynaecology, University of Sydney, Sydney, New South Wales 2006 Australia.

The synthetic steroid, danazol [17-pregna-2,4-dien-20-yno-(2,3,d)isoxazol-17-ol], is used widely for the treatment of endometriosis. In nine subjects studied over a 6-month course of treatment and for 5 months subsequently, plasma high density lipoprotein cholesterol (HDL-C) levels fell during treatment (P < 0.001) and were restored to pretreatment levels within 3–5 months after treatment ceased. In these patients, total cholesterol did not increase significantly, yet the depressed levels of HDL-C apparently masked an increase in the total cholesterol in the remaining lipoprotein classes (P < 0.01). Triglyceride levels were not affected significantly over the course of the treatment. Lipoprotein electrophoresis indicated an elevated β-lipoprotein band in the subjects using danazol. All effects of danazol on plasma levels of cholesterol and HDL-C were reversed within 3–5 months after the cessation of treatment.

Received December 23, 1980.

This article has been cited by other articles:

				A Fay and M Abinun Current management of hereditary angio-oedema (C'1 esterase inhibitor deficiency) J. Clin. Pathol., April 1, 2002; 55(4): 266 - 270. [Abstract] [Full Text] [PDF]

				P. D. Thompson, E. M. Cullinane, S. P. Sady, C. Chenevert, A. L. Saritelli, M. A. Sady, and P. N. Herbert Contrasting Effects of Testosterone and Stanozolol on Serum Lipoprotein Levels JAMA, February 24, 1989; 261(8): 1165 - 1168. [Abstract] [PDF]

				R. T. Kirkland, B. S. Keenan, J. L. Probstfield, W. Patsch, T.-L. Lin, G. W. Clayton, and W. Insull Jr Decrease in Plasma High-Density Lipoprotein Cholesterol Levels at Puberty in Boys With Delayed Adolescence: Correlation With Plasma Testosterone Levels JAMA, January 23, 1987; 257(4): 502 - 507. [Abstract] [PDF]